Last updated: October 30, 2023
Sponsor: Oyster Point Pharma, Inc.
Overall Status: Completed
Phase
2/3
Condition
Sjogren's Syndrome
Dry Eyes
Eyelid Inflammation
Treatment
OC-01 Low Dose, 0.12 mg/mL
Placebo (vehicle) nasal spray
OC-01 High Dose, 1.2 mg/mL
Clinical Study ID
NCT03920215
OPP-002-01EXT
Ages > 22 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Have been enrolled in the OPP-002 study
- Have received at least one dose of the study drug/placebo in OPP-002 study
- Completed the OPP-002 study to Visit 5
- Have provided verbal and written informed consent
Exclusion
Exclusion Criteria:
- Have discontinued prior to Visit 5 in the OPP-002 study.
Study Design
Total Participants: 101
Treatment Group(s): 4
Primary Treatment: OC-01 Low Dose, 0.12 mg/mL
Phase: 2/3
Study Start date:
August 15, 2018
Estimated Completion Date:
September 20, 2019
Study Description
Connect with a study center
Newport Beach
Newport Beach, California 92663
United StatesSite Not Available
Indianapolis
Indianapolis, Indiana 46290
United StatesSite Not Available
Andover
Andover, Massachusetts 01810
United StatesSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.